Jessica Leonard

Assistant Professor

Assistant Professor, Knight Cancer Institute

Emailleonard@ohsu.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Jessica Leonard is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

309 Citations
6 h-Index
10 Article
1 Comment/debate
1 Review article

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph⁺ ALL
Leonard, J. T., Kosaka, Y., Malla, P., LaTocha, D., Lamble, A., Hayes-Lattin, B., Byrd, K., Druker, B. J., Tyner, J. W., Chang, B. H. & Lind, E., Feb 18 2021, In: Blood. 137, 7, p. 939-944 6 p.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Functional characterization of two rare BCR-FGFR1⁺ leukemias
Barnes, E. J., Leonard, J., Medeiros, B. C., Druker, B. J. & Tognon, C. E., Oct 2020, In: Cold Spring Harbor Molecular Case Studies. 6, 2, 4838.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years
Lachowiez, C., Cook, R. J., Hayes-Lattin, B., Maziarz, R. T., Borate, U., Traer, E., Leonard, J., Newell, L., Dao, K. H. & Meyers, G., Jun 2019, In: Hematology/ Oncology and Stem Cell Therapy. 12, 2, p. 105-109 5 p.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML
Dunlap, J. B., Leonard, J., Rosenberg, M., Cook, R., Press, R., Fan, G., Raess, P. W., Druker, B. J. & Traer, E., Aug 2019, In: American Journal of Hematology. 94, 8, p. 913-920 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
6 Scopus citations
Functional genomic landscape of acute myeloid leukaemia
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, U., Bryant, J., Burke, R., Carlos, A., Carpenter, R., Carroll, J., Chang, B. H., Coblentz, C. & 68 others, d’Almeida, A., Cook, R., Danilov, A., Dao, K. H. T., Degnin, M., Devine, D., Dibb, J., Edwards, D. K., Eide, C. A., English, I., Glover, J., Henson, R., Ho, H., Jemal, A., Johnson, K., Johnson, R., Junio, B., Kaempf, A., Leonard, J., Lin, C., Liu, S. Q., Lo, P., Loriaux, M. M., Luty, S., Macey, T., MacManiman, J., Martinez, J., Mori, M., Nelson, D., Nichols, C., Peters, J., Ramsdill, J., Rofelty, A., Schuff, R., Searles, R., Segerdell, E., Smith, R. L., Spurgeon, S. E., Sweeney, T., Thapa, A., Visser, C., Wagner, J., Watanabe-Smith, K., Werth, K., Wolf, J., White, L., Yates, A., Zhang, H., Cogle, C. R., Collins, R. H., Connolly, D. C., Deininger, M. W., Drusbosky, L., Hourigan, C. S., Jordan, C. T., Kropf, P., Lin, T. L., Martinez, M. E., Medeiros, B. C., Pallapati, R. R., Pollyea, D. A., Swords, R. T., Watts, J. M., Weir, S. J., Wiest, D. L., Winters, R. M., McWeeney, S. K. & Druker, B. J., Oct 25 2018, In: Nature. 562, 7728, p. 526-531 6 p.
Research output: Contribution to journal › Article › peer-review
217 Scopus citations

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL

Functional characterization of two rare BCR-FGFR1+ leukemias

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML

Functional genomic landscape of acute myeloid leukaemia

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph⁺ ALL

Functional characterization of two rare BCR-FGFR1⁺ leukemias